Azemiglitazone
Azemiglitazone (MSDC-0602) is a novel insulin sensitizer designed to retain the effect of thiazolidinediones on mitochondrial pyruvate carriers with limited PPAR-gamma binding. It is hoped to have fewer adverse effects than the thiazolidinediones and is being developed by Cirius Therapeutics for type 2 diabetes and non-alcoholic fatty liver disease. It is formulated as its potassium salt (chemistry), salt, azemiglitazone potassium (MSDC-0602K). References

Experimental diabetes drugs Experimental drugs developed for non-alcoholic fatty liver disease Thiazolidinediones 3-Methoxyphenyl compounds Ketones Aromatic ethers {{gastrointestinal-drug-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]